RT Journal Article
SR Electronic
T1 L-Dopa-induced changes in aperiodic bursts dynamics relate to individual clinical improvement in Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.14.24308683
DO 10.1101/2024.06.14.24308683
A1 Agouram, Hasnae
A1 Neri, Matteo
A1 Angiolelli, Marianna
A1 Depannemaecker, Damien
A1 Bahuguna, Jyotika
A1 Schwey, Antoine
A1 Régis, Jean
A1 Carron, Romain
A1 Eusebio, Alexandre
A1 Malfait, Nicole
A1 Daucé, Emmanuel
A1 Sorrentino, Pierpaolo
YR 2024
UL http://medrxiv.org/content/early/2024/07/16/2024.06.14.24308683.abstract
AB Parkinson’s disease (PD) is a neurodegenerative disease primarily characterized by severe motor symptoms that can be transiently relieved by medication (e.g. levodopa). These symptoms are mirrored by widespread alterations of neuronal activities across the whole brain, whose characteristics at the large scale level are still poorly understood. To address this issue, we measured resting state activities of 11 PD patients using DBS contacts in the subthalamic nucleus (STN) and EEG electrodes over motor areas. Data were recorded for each patient before (OFF-condition) and after (ON-condition) levodopa administration. Neuronal avalanches, i.e. brief bursts of activity with widespread propagation, were detected and quantified on both types of contacts, and used to characterize differences in both conditions. Of particular interest, we noted a larger number of shorter and smaller avalanches in the OFF-condition, and a lesser number of wider and longer avalanches in the ON-condition. This difference turned out to be statistically significant at the group level. Then, we computed the avalanche transition matrices (ATM) to track the contact-wise patterns of avalanche spread. We observed a higher probability that an avalanche would spread within and between STN and motor cortex in the ON-state, with highly significant differences at the group level. Furthermore, we discovered that the increase in overall propagation of avalanches was correlated to clinical improvement after levodopa administration. Our study offers the initial cross-modality assessment of aperiodic activities in PD patients, including levodopa’s effects on cross-regional aperiodic bursts at the individual level, suggesting potential biomarkers for PD electrophysiological alterations.Significance Statement Our research focuses on levodopa’s effects on large-scale dynamics in PD using a novel approach involving aperiodic bursts (i.e., neuronal avalanches). To achieve this, we measured resting-state activities of 11 PD patients using DBS contacts in the STN and EEG electrodes placed bilaterally over the motor areas, both before and after levodopa administration. Unlike most studies on beta frequency (13–30 Hz) activities, we examined dynamics through aperiodic bursts across temporal and spatial scales. Instead of focusing on global properties, we tracked the spatial spread of neuronal avalanches across the brain. Our study provides the first assessment of levodopa’s effects on cross-regional aperiodic bursts within and between the STN and motor cortex, and suggests potential electrophysiological biomarkers for PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Agence Nationale de la Recherche (ANR-18-CE37-0018) SENCE and Ecole Centrale Méditerranée.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Comité de Protection des Personnes (CPP) Sud Méditerranée I gave ethical approval for this work. The registration number is RCB: 2009-A00913-54.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe codes employed in this study are available at https://github.com/Hasnae12/neuronal_avalanches_PD. However, due to the clinical nature of the data, it can’t be publicly available.